FDA Approves AstraZeneca’s New Breast‑Cancer Therapy Amid Access Hurdles Roivant’s Lung‑Targeted Therapy Nails Phase 2 Goal, Shares Jump to Record Levels Roivant’s Mosliciguat Shines in Phase 2, Sending ROIV Shares Toward All‑Time High Roivant’s Mosliciguat Shows Promise in Pulmonary Hypertension Trial